Axsome Therapeutics, Inc. (AXSM)

74,80 +0,61 (+0,82 %) À la clôture : 04:00PM EDT

Axsome Therapeutics, Inc.

One World Trade Center
22nd Floor
New York, NY 10007
United States
212 332 3241
https://www.axsome.com

Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 545

Dirigeants clés

Nom	Titre	Payer	Exercé	Année de naissance
Dr. Herriot Tabuteau M.D.	Founder, Chairman, CEO & President	1,4M	S.O.	1968
Mr. Mark L. Jacobson M.A.	Chief Operating Officer	835,84k	S.O.	1983
Mr. Hunter Murdock Esq.	General Counsel & Secretary	757,31k	S.O.	1980
Ms. Lori Englebert M.B.A.	Executive Vice President of Product Strategy	S.O.	S.O.	1978
Mr. Ari Maizel	Executive VP & Head of Commercial	S.O.	S.O.	S.O.

Les montants ont été établis en date du 31 décembre 2023 et les valeurs de compensation concernent le dernier exercice fiscal clos à cette date. Le terme « rémunération » désigne le salaire, les bonus, etc. Le terme « exercé » est utilisé pour la valeur des options exercées au cours de l’exercice fiscal. Devise exprimée en USD.

Description

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Gouvernance d’entreprise

L’ISS Governance QualityScore de Axsome Therapeutics, Inc. en date du 1 mai 2024 est 8. Les scores principaux sont Audit : 9; Société : 8; Droits des actionnaires : 8; Compensation : 8.

Résultats de gouvernance d’entreprise offerts par Institutional Shareholder Services (ISS). Les résultats indiquent un rang décile par rapport à l’indice ou à la région. Un résultat décile de 1 indique un risque de gouvernance faible, tandis que 10 indique un risque de gouvernance élevé.